YKYY033 injection, a subsidiary of Yuekang Pharmaceutical (688658.SH), obtained FDA clinical trial approval

Zhitong Finance App News, Yuekang Pharmaceutical (688658.SH) issued an announcement. The company's subsidiary Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd. recently received a letter from the US Food and Drug Administration (“FDA”) to agree to the clinical trial application of YKYY033 injection for the prevention and treatment of arteriovenous thrombosis.

According to reports, the product was approved for clinical trials by the National Drug Administration (NMPA) in June and July 2026 for various anticoagulant-related indications, and phase I clinical research is progressing steadily. This time, it successfully obtained clinical trial approval from the US FDA, marking that the product has officially obtained overseas clinical development qualifications. Relying on the approved full-scenario thrombus prevention and treatment indication matrix, the company will carry out differentiated clinical exploration of multiple indications, accurately target mainstream anticoagulant treatment guidelines and clinical standards around the world, and help fill the gaps in the global and domestic market for safe and long-lasting nucleic acid anticoagulants.